A common DNA variant near the PITX2 gene is the strongest and most consistently replicated genetic risk factor for atrial fibrillation, the most common irregular heart rhythm and a major cause of stroke.
Atrial fibrillation, often shortened to AFib or AF, is the most common sustained abnormal heart rhythm. Normally, the heart's upper chambers (the atria) contract in a coordinated rhythm set by a natural pacemaker. In atrial fibrillation, electrical activity in the atria becomes rapid and disorganized, so instead of contracting normally they quiver — and the lower chambers (ventricles) beat irregularly in response.
Symptoms of atrial fibrillation vary widely between people:
Importantly, a large proportion of people with atrial fibrillation notice no symptoms at all, and the condition is sometimes only discovered incidentally on an ECG done for another reason, or after a stroke.
When the atria quiver instead of contracting properly, blood can pool and form small clots, most often in a small pouch called the left atrial appendage. If a clot breaks free, it can travel to the brain and cause a stroke. Atrial fibrillation substantially increases stroke risk, and strokes associated with it tend to be more severe than strokes from other causes. This is why atrial fibrillation is taken seriously even when it causes few or no day-to-day symptoms, and why physicians use structured risk scores (weighing factors like age, blood pressure, diabetes, and prior stroke) to decide whether blood-thinning medication is warranted for a given patient.
Atrial fibrillation becomes dramatically more common with age. It affects millions of people in the United States alone, with the number expected to keep rising as the population ages, and lifetime risk estimates for adults in some populations approach roughly one in three to one in four. Other established risk factors include high blood pressure, obesity, diabetes, heart failure, sleep apnea, hyperthyroidism, and heavy alcohol use. Family history also matters — people with a close relative who has atrial fibrillation are at increased risk themselves, which is part of what pointed researchers toward a genetic contribution.
A small number of families carry rare, single-gene mutations that cause an inherited form of atrial fibrillation, usually appearing at an unusually young age. But for the vast majority of people who develop atrial fibrillation — including most older adults with the condition — no single rare mutation is responsible. Instead, genome-wide studies comparing the DNA of thousands of people with and without atrial fibrillation have identified dozens of common genetic variants, each contributing a small amount to overall risk. The single strongest and most consistently replicated of these sits near a gene called PITX2, on chromosome 4. It's important to be clear about what this means: carrying the risk version of this variant modestly increases the odds of eventually developing atrial fibrillation — it does not cause the condition outright, the way a single-gene mutation might, and most people who carry it never develop atrial fibrillation at all.
Atrial fibrillation is diagnosed with an electrocardiogram (ECG), which shows the characteristic irregular rhythm without the normal organized electrical signal from the atria. Because AF can come and go, longer-term monitoring — a portable ECG monitor worn for days to weeks, or increasingly a smartwatch or similar wearable sensor — is often used to catch episodes that a brief in-office ECG might miss.
Locus and lead variants. Genome-wide association studies first identified a susceptibility locus on chromosome 4q25, in a gene desert roughly 150 kb from PITX2 (paired-like homeodomain transcription factor 2), as strongly associated with atrial fibrillation. The original discovery (Gudbjartsson DF, et al., "Variants conferring risk of atrial fibrillation on chromosome 4q25." Nature, 2007;448(7151):353-357; PMID 17603472) reported two intergenic SNPs, rs2200733 and rs10033464, associated with AF in Icelandic, European, and Asian cohorts. rs10033464 (GWAS Catalog: chr4:110,799,605, GRCh38, intergenic/upstream) reached genome-wide significance with an odds ratio of approximately 1.39 (P ≈ 6.9×10⁻¹¹) per risk-allele copy in the discovery and replication cohorts, and has been examined in several later European-ancestry cohorts with variable results (reported ORs roughly 1.3-1.7, not all statistically significant), and at least one pooled meta-analysis of this SNP alone found no significant association (OR 1.21, 95% CI 0.97-1.50, with high between-study heterogeneity). The 4q25/PITX2 locus as a whole — and its neighboring variant rs2200733 in particular — replicates far more consistently than rs10033464 considered on its own; association at this specific SNP has been weaker or non-significant in some non-European cohorts, illustrating that GWAS effect sizes for common variants are not uniform across ancestries.
Mechanism (indirect, non-coding). Unlike a coding mutation that directly alters a protein, rs10033464 and related 4q25 variants lie in a non-coding regulatory region and are thought to act by modulating expression of PITX2 (specifically the PITX2c isoform) in the developing and adult left atrium, rather than by changing the PITX2 protein's structure. PITX2 is an atrial-selective transcription factor required for left-right patterning of the heart during development and for suppressing pacemaker activity outside the sinoatrial node in the adult left atrium; reduced PITX2 dosage in animal models produces electrical and structural remodeling of the atria that predisposes to fibrillation, including altered ion channel and calcium-handling gene expression and abnormalities of pulmonary vein tissue, a common site where the aberrant electrical signals that trigger AF originate. Because the risk variant only modestly shifts a regulatory process rather than eliminating a protein's function, its effect on any one individual's risk is correspondingly modest — this is a risk-modifying common variant, not a Mendelian cause.
Distinguishing common-variant AF risk from monogenic familial AF. A minority of atrial fibrillation, especially early-onset or strongly familial cases, is caused by rare, highly penetrant variants in genes including KCNQ1, KCNA5, SCN5A, NPPA, GJA5, and others, generally following an autosomal dominant pattern (collectively cataloged under the "familial atrial fibrillation" OMIM entries, e.g., ATFB1 through numbered subtypes). These are mechanistically distinct from the common 4q25/PITX2 regulatory variant discussed here: familial AF genes typically encode ion channel or structural proteins directly, produce disease with much higher penetrance within affected families, and often present at a younger age. The PITX2-region variant, by contrast, is common in the general population (found in a substantial minority of people) and contributes only a small, probabilistic increment to lifetime risk, more analogous to other common cardiovascular GWAS loci than to a single-gene cardiac channelopathy.
Diagnosis and risk stratification (general, not variant-specific). AF is diagnosed by ECG showing an irregularly irregular rhythm without discernible P waves; ambulatory or wearable monitoring increases detection of paroxysmal (intermittent) episodes. Stroke risk in diagnosed AF is stratified clinically using scores such as CHA₂DS₂-VASc, which incorporate age, sex, and comorbidities rather than genotype; genetic risk variants such as rs10033464 are not currently part of validated clinical stroke-risk calculators and are used mainly in research settings.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Atrial Fibrillation (PITX2 Genetic Risk) comes down to these specific, well-studied positions — not a diagnosis.
No. This variant modestly increases the odds of developing atrial fibrillation over a lifetime — by roughly 30-70% per copy in most studies — but it does not cause the condition by itself. Most people who carry it never develop atrial fibrillation, and many people who do develop it do not carry this particular variant.
No. A minority of atrial fibrillation, especially cases appearing at a young age or clustering strongly in families, is caused by rare mutations in different genes (such as KCNQ1 or SCN5A) that directly disrupt heart electrical proteins and are inherited in a straightforward autosomal dominant pattern. The PITX2-region variant is a much more common, weaker risk factor that works differently.
Because it raises the risk of stroke regardless of whether it causes symptoms. Blood can pool and clot in the quivering atria, and a piece of that clot can travel to the brain. This is why atrial fibrillation found incidentally is still taken seriously and often treated.
With an electrocardiogram (ECG), which shows an irregular rhythm without normal, organized atrial electrical activity. Because episodes can come and go, doctors sometimes use longer-term monitors or wearable devices to catch intermittent episodes that a single office visit ECG might miss.
That is a question for a physician, factoring in the full clinical picture — age, blood pressure, other heart conditions, and symptoms — rather than genotype alone. Genetic risk variants like this one are not currently part of standard clinical stroke-risk or monitoring calculators.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.